United States

New DEXDOMITOR 0.1 Designed Specifically For Small Dogs And Cats

Latest study shows majority of pets struggle during routine veterinarian visits

FLORHAM PARK, N.J., June 19, 2014 —Zoetis Inc. today announced a lower concentration of DEXDOMITOR® (dexmedetomidine), a sedative and preanesthetic. The 0.1 mg/ml dosage is designed to make it more convenient for veterinarians to accurately administer doses for dogs less than 20 pounds and cats less than seven pounds.
 
“DEXDOMITOR and now DEXDOMITOR 0.1 allow veterinarians and their staff to perform minor procedures on small dogs and cats, which they might not be able to do if the pet were struggling or resisting being held by staff members,” said J. Michael McFarland, DVM, DABVP and group director of Companion Animal Veterinary Operations for Zoetis. “Using a sedation protocol helps enhance the comfort and safety of the pet and the staff and provides a more positive clinic visit for the client as well.”

Smaller patients require smaller volumes of DEXDOMITOR, which can be challenging to measure accurately. Since DEXDOMITOR 0.1 is one-fifth (1/5) the original concentration, dose volumes can be more accurately measured without the need for dilution. Sedation and preanesthesia protocols can therefore be tailored to the individual patient, helping to ensure consistent and predictable outcomes. The new concentration has been used in Europe since August 2013.

New Survey Reveals Struggling Among Pets Common During Vet Visits
According to a March 2014 survey conducted by Harris Poll on behalf of Zoetis, 56 percent of dog owners and 50 percent of cat owners notice their pet struggling during routine veterinary visits and procedures. Additionally, the survey revealed:

  • The most common behavior reported by owners was trembling (24 percent of cats and 37 percent of dogs) followed by resisting being held (24 percent of cats and 18 percent of dogs).
  • Fourteen percent of dog and cat owners indicated more than one person was needed to hold their pet during examination.
  • Nine percent of dog and cat owners revealed that their pet even displayed aggression when visiting the veterinarian.

“We are pleased to offer veterinarians this lower concentration formulation DEXDOMITOR,” Dr. McFarland said. “This formulation is more convenient to use in small dogs and cats and can help increase clinic efficiency.”

For more information on DEXDOMITOR 0.1, visit www.precisionsedation.com.

IMPORTANT SAFETY INFORMATION

Do not use DEXDOMITOR or DEXDOMITOR 0.1 in dogs or cats, and ANTISEDAN in dogs, with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. DEXDOMITOR and DEXDOMITOR 0.1 should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists with DEXDOMITOR and DEXDOMITOR 0.1. The use of DEXDOMITOR and DEXDOMITOR 0.1 as a preanesthetic in dogs and cats significantly reduces the amount of induction and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation may occur with DEXDOMITOR and DEXDOMITOR 0.1 use. Severe dyspnea and respiratory crackles due to acute or delayed pulmonary edema could develop in cats. DEXDOMITOR and DEXDOMITOR 0.1 have not been evaluated for use in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats younger than 12 weeks of age; or in geriatric dogs or cats. Occasional vomiting may occur with ANTISEDAN use. Rarely, a brief state of excitement or apprehensiveness may be seen in ANTISEDAN-treated dogs. Other potential side effects of α2-antagonists, such as ANTISEDAN, include hypersalivation, diarrhea, and tremors. See full Prescribing Information, attached See full Prescribing Information for DEXDOMITOR and DEXDOMITOR 0.1, and ANTISEDAN here.

Survey Methodology

This survey was conducted online within the United States by Harris Poll on behalf of Zoetis from March 20-24, 2014 among 349 U.S. adult cat owners and 561 U.S. adult dog owners ages 18 and older. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables, please contact Gary Kreckmann, 973-822-7222 or Gary.Kreckmann@zoetis.com.

About Zoetis

Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information, visit www.zoetis.com.
 
Zoetis is the proud sponsor with the Smithsonian Institution Traveling Exhibition Service, the American Veterinary Medical Association, and the American Veterinary Medical Foundation of the mobile educational exhibit Animal Connections: Our Journey Together. Families visiting the exhibit will explore the vast bonds between people and animals and learn about the important role veterinarians play in protecting animal and human health.


For further information, Contact:

Gary Kreckmann
Zoetis
973-822-7222
Gary.Kreckmann@zoetis.com

Julie Lux
archer>malmo
901-500-7063
jlux@archermalmo.com